ClinicalTrials.gg
CompletedNCT03775200P-TRDUpdated Apr 24, 2023Results posted

The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression

A Phase 2 interventional study of Psilocybin in Treatment Resistant Depression, sponsored by COMPASS Pathways. Completed at 25 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-24.

Sponsored by COMPASS Pathways · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
233
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing psilocybin in Depressive Disorder, Treatment-Resistant — 9 open to participants now, 14 under way, 2 of them phase 3. Psilocybin · Depressive Disorder, Treatment-Resistant.

Enrollment
3rd of 25
233 · median 30
Started
2019
the only one that year
Phase 2
18 of 25
8 open now
Registered
1st of 25
by date
Lead sponsor
4 of 25
COMPASS Pathways

Among the 25 studies testing psilocybin in Depressive Disorder, Treatment-Resistant, this one is the 3rd largest by enrollment, is the only one that started in 2019, is one of 18 in phase 2, and was the 1st registered.

Depressive Disorder, Treatment-Resistant

448 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 147 are open to participants now.

Browse Depressive Disorder, Treatment-Resistant studies →

Open to participants now

9 of the 25 studies testing psilocybin in Depressive Disorder, Treatment-Resistant are open now, in 6 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About psilocybin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 114 Depressive Disorder, Treatment-Resistant studies recruiting now, 26 (23%) set no upper age limit and 76 (67%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing psilocybin in Depressive Disorder, Treatment-Resistant, or all of them as a file.
02

Study summary

The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression

Read the detailed description

The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression - a dose-ranging study

03

Conditions studied

  • Treatment Resistant Depression
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of TRD

Exclusion criteria

Exclusion Criteria:

  • Other comorbidities
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
233 participants (actual)

Study arms

  • Experimental
    Low dose

    Low dose Psilocybin

    Drug: Psilocybin

  • Experimental
    Medium dose

    Medium dose Psilocybin

    Drug: Psilocybin

  • Experimental
    High dose

    High dose Psilocybin

    Drug: Psilocybin

Interventions

06

What researchers measure

Primary outcomes

  1. Montgomery Asberg Depression Rating Scale (MADRS) Change From Baseline to Week 3

    MADRS is a clinician-rated scale measuring depression symptom severity, consisting of 10 items, each scored from 0 (normal) to 6 (severe), for a total possible score of between 0 to 60; higher scores denote greater severity. Response \>= 50% decrease and remission \<= 10 total score.

    Time frame: Change from Baseline to Week 3

  2. MADRS Change From Baseline to Week 3, Sensitivity Analysis

    MADRS is a clinician-rated scale measuring depression symptom severity, consisting of 10 items, each scored from 0 (normal) to 6 (severe), for a total possible score of between 0 to 60; higher scores denote greater severity. Response \>= 50% decrease and remission \<= 10 total score.

    Time frame: Change from Baseline to Week 3

07

Results

Posted Apr 24, 2023

Participant flow

First patient first visit: 1 March 2019 Last patients last visit: 27 September 2021

Participant flow — Overall Study
Milestone25 mg COMP360 Psilocybin10 mg COMP360 Psilocybin1 mg COMP360 Psilocybin
Started797579
Completed746669
Not completed5910

Outcome measures

PrimaryMontgomery Asberg Depression Rating Scale (MADRS) Change From Baseline to Week 3

MADRS is a clinician-rated scale measuring depression symptom severity, consisting of 10 items, each scored from 0 (normal) to 6 (severe), for a total possible score of between 0 to 60; higher scores denote greater severity. Response \>= 50% decrease and remission \<= 10 total score.

Time frame:
Change from Baseline to Week 3
Reported as:
Mean · units on a scale
Montgomery Asberg Depression Rating Scale (MADRS) Change From Baseline to Week 3
units on a scale25 mg COMP360 Psilocybin10 mg COMP360 Psilocybin1 mg COMP360 Psilocybin
Montgomery Asberg Depression Rating Scale (MADRS) Change From Baseline to Week 3-12 ± 12.98-8.9 ± 10.94-6.8 ± 11.10
Statistical analysis
  • 25 mg COMP360 Psilocybin vs 1 mg COMP360 Psilocybin · Mixed Models Analysis · p = <0.05 · Least mean square difference: -6.6 · 95% CI -10.2 to -2.9LSM difference of COMP360 25 mg compared to COMP360 1 mg.
PrimaryMADRS Change From Baseline to Week 3, Sensitivity Analysis

MADRS is a clinician-rated scale measuring depression symptom severity, consisting of 10 items, each scored from 0 (normal) to 6 (severe), for a total possible score of between 0 to 60; higher scores denote greater severity. Response \>= 50% decrease and remission \<= 10 total score.

Time frame:
Change from Baseline to Week 3
Reported as:
Mean · units on a scale
MADRS Change From Baseline to Week 3, Sensitivity Analysis
units on a scale25 mg COMP360 Psilocybin10 mg COMP360 Psilocybin1 mg COMP360 Psilocybin
MADRS Change From Baseline to Week 3, Sensitivity Analysis-12 ± 12.98-8.9 ± 11.11-6.7 ± 11.18
Statistical analysis
  • 25 mg COMP360 Psilocybin vs 1 mg COMP360 Psilocybin · Mixed Models Analysis · p = <0.05 · Least mean square difference: -5.6 · 95% CI -9.4 to -1.8Hypothetical strategy estimand - MNAR and MAR imputation for missing data.

Adverse events

Collected over Up to 12 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
25 mg COMP360 Psilocybin0/79 (0%)5/79 (6.3%)60/79 (75.9%)
10 mg COMP360 Psilocybin0/75 (0%)6/75 (8%)51/75 (68%)
1 mg COMP360 Psilocybin0/79 (0%)1/79 (1.3%)50/79 (63.3%)
Most frequent serious events
Most frequent serious events
Event25 mg COMP360 Psilocybin10 mg COMP360 Psilocybin1 mg COMP360 Psilocybin
Suicidal behaviourPsychiatric disorders3/790/750/79
Intentional self-injuryPsychiatric disorders2/792/751/79
Suicidal ideationPsychiatric disorders2/792/750/79
DepressionPsychiatric disorders0/791/750/79
HospitalisationSurgical and medical procedures0/791/750/79
Drug withdrawal syndromeGeneral disorders1/790/750/79
Adjustment disorder with anxietyPsychiatric disorders1/790/750/79
Adjustment disorder with mixed anxiety and depressed moodPsychiatric disorders1/790/750/79
Most frequent other events
Showing 10 of 18
Most frequent other events
Event25 mg COMP360 Psilocybin10 mg COMP360 Psilocybin1 mg COMP360 Psilocybin
HeadacheNervous system disorders27/7916/7520/79
NauseaGastrointestinal disorders18/797/754/79
InsomniaPsychiatric disorders8/7911/7514/79
AnxietyPsychiatric disorders7/7913/753/79
FatigueGeneral disorders12/795/757/79
Mood alteredPsychiatric disorders7/793/751/79
Back painMusculoskeletal and connective tissue disorders6/790/753/79
DizzinessNervous system disorders6/791/751/79
DepressionPsychiatric disorders4/795/755/79
Euphoric moodPsychiatric disorders4/795/754/79

Baseline characteristics

The Safety Analysis Set included all randomised participants who received study drug.

Age, Categorical
Age, Categorical(Participants)25 mg COMP360 Psilocybin10 mg COMP360 Psilocybin1 mg COMP360 PsilocybinTotal
<=18 years0000
Between 18 and 65 years767377226
>=65 years3227
Age, Continuous
Age, Continuous(years)25 mg COMP360 Psilocybin10 mg COMP360 Psilocybin1 mg COMP360 PsilocybinTotal
Mean40.2 ± 12.1940.6 ± 12.7638.7 ± 11.7139.8 ± 12.19
Sex: Female, Male
Sex: Female, Male(Participants)25 mg COMP360 Psilocybin10 mg COMP360 Psilocybin1 mg COMP360 PsilocybinTotal
Female353443112
Male444136121
Race (NIH/OMB)
Race (NIH/OMB)(Participants)25 mg COMP360 Psilocybin10 mg COMP360 Psilocybin1 mg COMP360 PsilocybinTotal
American Indian or Alaska Native0000
Asian43512
Native Hawaiian or Other Pacific Islander0000
Black or African American4015
White707273215
More than one race0000
Unknown or Not Reported1001
Region of Enrollment
Region of Enrollment(participants)25 mg COMP360 Psilocybin10 mg COMP360 Psilocybin1 mg COMP360 PsilocybinTotal
Canada2226
Netherlands17161750
United States32323296
Czechia3227
Ireland33511
Denmark3238
United Kingdom11101233
Portugal1012
Germany2204
Spain56516
08

Study locations

25 sites
  • Kadima Neuropsychiatry Institute
    La Jolla, California 92037, United States
  • Altman Clinical and Translational Research Institute, University of California
    San Diego, California 92093, United States
  • Stanford Department of Psychiatry
    Stanford, California 94305, United States
  • Mood and Anxiety Disorders Program Emory University School of Medicine
    Atlanta, Georgia 30329, United States
  • Ray Worthy Psychiatry LLC
    New Orleans, Louisiana 70123, United States
  • Sheppard Pratt Health System
    Baltimore, Maryland 21204, United States
  • New York State Psychiatric Institute
    New York, New York 10032, United States
  • UT Center of Excellence on Mood Disorders, University of Texas Health Science Center
    Houston, Texas 77054, United States
  • Canadian Rapid Treatment Centre of Excellence
    Mississauga, Ontario, Canada
  • Centre for Addiction and Mental Health
    Toronto, Ontario, Canada
  • National Institute of Mental Health Czech Republic
    Klecany, Czechia
  • Enhed for Psykiatrisk Forskning, Psykiatrien i Aalborg
    Aalborg, Denmark
  • Charité - Universitätsmedizin Berlin, Department of Psychiatry and Psychotherapy, Campus Benjamin Franklin
    Berlin, 12203, Germany
  • Tallaght University Hospital
    Dublin, Ireland
  • Groningen University Medical Centre
    Groningen, Netherlands
  • Leiden University Medical Centre
    Leiden, Netherlands
  • Utrecht University Medical Centre
    Utrecht, Netherlands
  • Unidade de Neuropsiquiatria, Centro Clinico Champalimaud
    Lisboa, Portugal
  • Hospital de Dia Numancia
    Barcelona, Spain
  • Institute Hospital del Mar of Medical Research (IMIM)
    Barcelona, Spain
  • Clinical Research and Imaging Centre
    Bristol, Avon, United Kingdom
  • Wolfson Research Centre, Campus for Ageing and Vitality
    Newcastle Upon Tyne, Tyne And Wear NE4 5PL, United Kingdom
  • St. Pancras Clinical Research
    London, EC2Y 8EA, United Kingdom
  • Kings College London, Institute of Psychiatry, Psychology and Neurology
    London, United Kingdom
  • Greater Manchester Mental Health Foundation Trust
    Manchester, United Kingdom
09

References and documents

Publications

  • Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, Bird C, Blom RE, Brennan C, Brusch D, Burke L, Campbell-Coker K, Carhart-Harris R, Cattell J, Daniel A, DeBattista C, Dunlop BW, Eisen K, Feifel D, Forbes M, Haumann HM, Hellerstein DJ, Hoppe AI, Husain MI, Jelen LA, Kamphuis J, Kawasaki J, Kelly JR, Key RE, Kishon R, Knatz Peck S, Knight G, Koolen MHB, Lean M, Licht RW, Maples-Keller JL, Mars J, Marwood L, McElhiney MC, Miller TL, Mirow A, Mistry S, Mletzko-Crowe T, Modlin LN, Nielsen RE, Nielson EM, Offerhaus SR, O'Keane V, Palenicek T, Printz D, Rademaker MC, van Reemst A, Reinholdt F, Repantis D, Rucker J, Rudow S, Ruffell S, Rush AJ, Schoevers RA, Seynaeve M, Shao S, Soares JC, Somers M, Stansfield SC, Sterling D, Strockis A, Tsai J, Visser L, Wahba M, Williams S, Young AH, Ywema P, Zisook S, Malievskaia E. Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. N Engl J Med. 2022 Nov 3;387(18):1637-1648. doi: 10.1056/NEJMoa2206443. PubMed 36322843 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2019 to primary completion in Jul 2021, 28 months.

Results were first posted in Apr 2023, 1 year 8 months after primary completion.

Of 50 phase 2 interventional studies under Depressive Disorder, Treatment-Resistant, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 41. This study's 28 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2018
First posted
Dec 13, 2018
StartActual
Mar 1, 2019
Primary completionActual
Jul 30, 2021
CompletionActual
Sep 27, 2021
Results first posted
Apr 24, 2023
Last update
Apr 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03775200
Lead sponsor
COMPASS Pathways
Responsible party
Sponsor
First posted
Dec 13, 2018
Start date
Mar 1, 2019
Primary completion
Jul 30, 2021
Completion
Sep 27, 2021
Results posted
Apr 24, 2023
Last update
Apr 24, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Psilocybin

Start the discussion